Editorial comment on: External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.

摘要

In the recent past, prognostics and outcomes research in oncology have received increasing attention from the medical community [1]. There has been a gradual shift from the use of a few clinicopathologic factors as prognosticators through the adoption of more sophisti cated multivariable risk-factor models to the introduction of molecular and genetic markers.